(Q38077699)

28 August 2017

1 reference

title

The pharmacology of Tourette syndrome (English)

1 reference

28 August 2017

1 reference

1 reference

Roji Thomas

1

1 reference

PubMed ID

23361655

28 August 2017

Andrea E Cavanna

series ordinal

2

1 reference

28 August 2017

30 January 2013

1 reference

Journal of Neural Transmission

28 August 2017

1 reference

28 August 2017

120

1 reference

28 August 2017

4

1 reference

28 August 2017

689-694

1 reference

https://scigraph.springernature.com/pub.10.1007/s00702-013-0979-z

28 August 2017

0 references

cites work

Treatment approaches in Gilles de la Tourette syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

European clinical guidelines for Tourette syndrome and other tic disorders. Part I: assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

Tolerability profile of aripiprazole in patients with Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

Treatment strategies for tics in Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

Update on the role of antipsychotics in the treatment of Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

Long-term effects of tetrabenazine in hyperkinetic movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

Nicotine potentiation of haloperidol in reducing tic frequency in Tourette's disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

European clinical guidelines for Tourette syndrome and other tic disorders. Part IV: deep brain stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

What patients with gilles de la tourette syndrome should be treated with deep brain stimulation and what is the best target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

Tourette's syndrome and role of tetrabenazine: review and personal experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

Gilles de la Tourette syndrome: the complexities of phenotype and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: a cross-cultural perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

A placebo-controlled trial of risperidone in Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

Contemporary assessment and pharmacotherapy of Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

Canadian guidelines for the evidence-based treatment of tic disorders: behavioural therapy, deep brain stimulation, and transcranial magnetic stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

European clinical guidelines for Tourette syndrome and other tic disorders. Part III: behavioural and psychosocial interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-013-0979-Z

Tourette syndrome: a follow-up study

21 January 2018

1 reference

12 December 2020

The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double-blind placebo-controlled study with clonidine and desipramine.

1 reference

12 December 2020

[A multicenter controlled study on aripiprazole treatment for children with Tourette syndrome in China]

1 reference

12 December 2020

Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome

1 reference

12 December 2020

The behavioral spectrum of Gilles de la Tourette syndrome

1 reference

12 December 2020

Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol

1 reference

12 December 2020

Clonidine and clonazepam in Tourette syndrome

1 reference

12 December 2020

The prognosis of Tourette syndrome: implications for clinical practice

1 reference

12 December 2020

Treatment of Gilles de la Tourette's Syndrome With Clonidine and Neuroleptics

1 reference

12 December 2020

Pimozide for tics in Tourette's syndrome

1 reference

12 December 2020

Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial.

1 reference

12 December 2020

Management of Gilles de la Tourette syndrome using sulpiride.

1 reference

12 December 2020

10.1007/S00702-013-0979-Z

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23361655